Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on ARS Pharmaceuticals (SPRY – Research Report), Wave Life Sciences (WVE – Research Report) and AC Immune SA (ACIU – Research Report).
ARS Pharmaceuticals (SPRY)
In a report issued on November 9, Roanna Ruiz from Leerink Partners maintained a Hold rating on ARS Pharmaceuticals, with a price target of $3.00. The company’s shares closed last Monday at $4.00.
According to TipRanks.com, Ruiz is ranked 0 out of 5 stars with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for ARS Pharmaceuticals with a $8.00 average price target.
See today’s best-performing stocks on TipRanks >>
Wave Life Sciences (WVE)
In a report issued on November 9, Joseph Schwartz from Leerink Partners reiterated a Hold rating on Wave Life Sciences, with a price target of $5.00. The company’s shares closed last Monday at $5.19.
According to TipRanks.com, Schwartz is ranked 0 out of 5 stars with an average return of
Wave Life Sciences has an analyst consensus of Moderate Buy, with a price target consensus of $9.00, representing a 72.1% upside. In a report issued on November 9, RBC Capital also maintained a Hold rating on the stock with a $5.00 price target.
AC Immune SA (ACIU)
In a report issued on November 9, Marc Goodman from Leerink Partners maintained a Buy rating on AC Immune SA. The company’s shares closed last Monday at $2.90.
According to TipRanks.com, Goodman is a 2-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for AC Immune SA with a $16.00 average price target, implying a 449.8% upside from current levels. In a report issued on November 6, H.C. Wainwright also reiterated a Buy rating on the stock with a $16.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on SPRY:
- ARS Pharmaceuticals reports Q3 EPS (16c), consensus (18c)
- ARS Pharmaceuticals presents clinical data on neffy for allergic reactions
- ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis
- ARS Pharmaceuticals announces scheduling of Type A meeting with FDA for neffy
- ARS Pharmaceuticals Announces Scheduling of a Type A Meeting with the U.S. FDA for neffy® (epinephrine nasal spray)
